OncoSec Medical Inc (ONCSQ)

[$Moneypenny$]

Yah. I don't think the partner for neopulse is going to be the same partner for phase 2b. I have a feeling the neopulse will be a narrow partnership limited to just that and not a throw in piece with a larger partnership.

I think the main issue is how extensive a partnership is the partnership with the anti Pd-1 going to be. For example, if you are going to do a combo trial with anti pd-1 for melanoma, why wouldn't you start the phase 1 breast trial also using a combination approach? Make sense to me. If il-12 turns non-responders into responders then that wouldn't that apply to other types of tumors?

I think oncs wants a partner that will finance both it's melanoma and other solid tumor indications. I can just see it now: Ali Daud presenting data for combination trials at ASCO 2015. Of the charts!!!